Trial reportClinical nutrition (Edinburgh, Scotland)2026
Effect of moderate or high versus low dose daily vitamin D on COVID-19 incidence: A double-blind, parallel-group randomized clinical trial.
Trial report in Clinical nutrition (Edinburgh, Scotland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04868903 (Low vs. Moderate to High Dose Vitamin D for Prevention of COVID-19), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Low vs. Moderate to High Dose Vitamin D for Prevention of COVID-19
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
BACKGROUND &
aimsVitamin D affects immune function and is associated with lower COVID-19 risk in observational studies. However, randomized clinical trials vary in whether they find vitamin D supplementation affects COVID-19 risk. The objective of this trial was to determine whether moderate or high dose vitamin D (4000 or 10,000 IU/day) versus low dose vitamin D (400 IU/day) affects COVID-19 risk.
methodsWe conducted a double-blind, parallel-group randomized trial (clinicaltrials.gov, NCT0486890) enrolling participants from December 5, 2020 to May 23, 2023 who chose between study branches comparing moderate versus low dose or high versus low dose vitamin D for up to 9 months and were randomized between the doses in their chosen branch. Recruitment occurred at UChicago Medicine or Rush University Medical Center. Eligibility criteria excluded persons with increased risk from vitamin D supplementation. Recruitment concluded March 30, 2023, with 955 participants randomized, and 923 continuing their participation until receipt of study vitamin D, including 324 high-versus-low branch participants. The primary outcome was time from randomization to COVID-19 infection.
resultsCOVID-19 risk was not lower for pooled moderate or high versus low dose (10.9% (50/461) versus 14.7% (68/462), aHR:0.73; 95%-CI:0.51-1.06; P = 0.10). In prespecified secondary analyses, COVID-19 risk was lower for moderate versus low dose (aHR:0.62; 95%-CI:0.39-0.99; P = 0.045) but not high versus low dose (aHR:0.99; 95%-CI:0.53-1.86; P = 0.98). Prespecified time-varying analyses controlling for post-randomization 25(OH)D levels found similar treatment effects, with no effects of 25(OH)D levels on risk. In a final prespecified analysis, among 130 seroconverting participants, COVID-19 was not reported less for pooled moderate or high versus low dose (aOR:0.62; 95%-CI:0.27-1.41; P = 0.25) and moderate versus low dose (aOR:0.37; 95%-CI:0.13-1.04; P = 0.06).
conclusionModerate or high versus low dose vitamin D supplementation did not decrease COVID-19 risk, but effects may vary by dose. Further study is warranted of the effects of higher doses and 25(OH)D levels on COVID-19 and other viral respiratory tract infections, and whether these infections become clinically evident.
trial registrationclinicaltrials.gov, NCT04868903, https://clinicaltrials.gov/study/NCT04868903.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.